Opaleye Management’s Cytokinetics CYTK Stock Holding History

Opaleye Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-75,300	Closed	-$3.98M	–	44
2024 Q3	$3.98M	Sell	75,300 -123,200	-62%	-$6.87M	0.66%	27
2024 Q2	$10.8M	Buy	+198,500	New	+$12M	2.46%	8
2023 Q3	–	Sell	-130,000	Closed	-$4.24M	–	44
2023 Q2	$4.24M	Sell	130,000 -77,500	-37%	-$2.87M	1.01%	26
2023 Q1	$7.3M	Sell	207,500 -42,500	-17%	-$1.73M	2.19%	12
2022 Q4	$11.5M	Sell	250,000 -13,000	-5%	-$559K	3.98%	6
2022 Q3	$12.7M	Sell	263,000 -39,500	-13%	-$1.9M	5.26%	6
2022 Q2	$11.9M	Sell	302,500 -104,000	-26%	-$4.19M	5.36%	5
2022 Q1	$15M	Sell	406,500 -173,500	-30%	-$6.16M	4.65%	6
2021 Q4	$26.4M	Hold	580,000	–	–	5.61%	6
2021 Q3	$20.7M	Hold	580,000	–	–	3.87%	8
2021 Q2	$11.5M	Hold	580,000	–	–	1.91%	16
2021 Q1	$13.5M	Sell	580,000 -2,800	-0.5%	-$59.8K	1.98%	15
2020 Q4	$12.1M	Buy	582,800 +374,000	+179%	+$6.84M	1.58%	19
2020 Q3	$4.52M	Sell	208,800 -94,250	-31%	-$2.2M	0.88%	35
2020 Q2	$7.14M	Buy	+303,050	New	+$5.68M	1.44%	25
2019 Q4	–	Sell	-650,000	Closed	-$7.4M	–	49
2019 Q3	$7.4M	Sell	650,000 -250,000	-28%	-$3.14M	2.67%	16
2019 Q2	$10.1M	Buy	900,000 +50,000	+6%	+$482K	3.09%	13
2019 Q1	$6.88M	Buy	+850,000	New	+$6.25M	1.9%	23

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Opaleye Management's CYTK Position: Q4 2024 in Review

Opaleye Management sold out of Cytokinetics (CYTK) in Q4 2024, closing a stake of 75,300 shares — an estimated $3.98M sold.

Opaleye Management first reported a position in CYTK in Q1 2019 and held it in 18 quarters. The position peaked at $26.4M in Q4 2021. 347 funds tracked by Wall St. Rank hold CYTK as of Q4 2024.

Opaleye Management reported no remaining Cytokinetics position as of Q4 2024 after selling out during the quarter.
Opaleye Management sold 75,300 Cytokinetics shares in Q4 2024, an estimated $3.98M.
Opaleye Management first reported a position in Cytokinetics in Q1 2019 and held it in 18 quarters.
Opaleye Management's Cytokinetics position peaked at $26.4M in Q4 2021.
347 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2024.

Based on Opaleye Management's 13F filing for Q4 2024, filed 14 Feb 2025.